IDT
| Code | Size | Price |
|---|
| TAR-T25525-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T25525-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T25525-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
IDT is an orally active TNFα modulator. It acts by altering neutrophil infiltration, improving cognition and diminishing tau and amyloid pathology in the 3xTgAD mouse model.
CAS:
18138-19-7
Formula:
C8H5NS2
Molecular Weight:
179.26
Purity:
0.98
SMILES:
S=C1NC(=S)c2ccccc12
References
1. McGill M, Blonde L, Chan JCN, Khunti K, Lavalle FJ, Bailey CJ; Global Partnership for Effective Diabetes Management. The interdisciplinary team in type 2 diabetes management: Challenges and best practice solutions from real-world scenarios. J Clin Transl Endocrinol. 2016 Dec 9;7:21-27. doi: 10.1016/j.jcte.2016.12.001. eCollection 2017 Mar. Review. PubMed PMID: 29067246; PubMed Central PMCID: PMC5651292.
2. Tiberi S, Carvalho AC, Sulis G, Vaghela D, Rendon A, Mello FC, Rahman A, Matin N, Zumla A, Pontali E. The cursed duet today: Tuberculosis and HIV-coinfection. Presse Med. 2017 Mar;46(2 Pt 2):e23-e39. doi: 10.1016/j.lpm.2017.01.017. Epub 2017 Feb 28. Review. PubMed PMID: 28256380.
3. Iwamura A, Nakajima M, Oda S, Yokoi T. Toxicological potential of acyl glucuronides and its assessment. Drug Metab Pharmacokinet. 2017 Feb;32(1):2-11. doi: 10.1016/j.dmpk.2016.11.002. Epub 2016 Nov 23. Review. PubMed PMID: 28017536.
4. Hirayama N. Docking simulations between drugs and HLA molecules associated with idiosyncratic drug toxicity. Drug Metab Pharmacokinet. 2017 Feb;32(1):31-39. doi: 10.1016/j.dmpk.2016.10.002. Epub 2016 Oct 18. Review. PubMed PMID: 27964952.